ERNA · Ernexa Therapeutics Inc. · Exempt Offerings
$2.18
+0.20 (+10.10%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of June 30, 2026, the Company had approximately $5.0 million in cash, which is less than that needed to effect its current operating plan and forecasted cash requirements for the next twelve months. However, management expects that its ability to access capital under its ATM will cover shortfalls in its cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$3.23M
Shares
1.63M
Volume · Oct 20
47.96K
Avg daily vol (3M)
56.94K
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2025-04-11 | New | Biotechnology | $7,249,999 | $7,249,999 | 06b |
| 2024-11-14 | New | Biotechnology | $3,887,252 | $3,887,252 | 06b |
| 2024-11-14 | New | Biotechnology | $1,137,746 | $1,137,746 | 06b |
| 2023-12-20 | New | Biotechnology | $9,193,000 | $7,788,000 | 06b |
| 2023-07-26 | New | Biotechnology | $8,715,000 | $8,715,000 | 06b |
| 2023-07-26 | New | Biotechnology | $8,715,000 | $8,715,000 | 06b |
| 2022-12-16 | New | Biotechnology | $7,712,874 | $7,712,874 | 06b |
| 2022-03-23 | New | Biotechnology | $12,000,000 | $12,000,000 | 06b |
Showing 1–8 of 8 filings